Trial Profile
Phase II/III trial of daclizumab for the prevention of graft versus host disease in patients with haematological malignancies or aplastic anaemia undergoing allogeneic bone marrow transplantation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Ciclosporin; Ciclosporin; Methotrexate
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 22 Jan 2013 New trial record